Many biomarkers for Alzheimer’s disease have been identified including:
Several plasma-based assays are also gaining accuracy in their ability to identify Alzheimer’s disease.
- amyloid load in the brain
- amyloid and tau proteins in the CSF
- metabolic activity in the brain
- various relative measures of brain atrophy.
However, no single biomarker has yet been shown to distinguish Alzheimer’s from non-Alzheimer’s with an acceptable level of accuracy to provide clinical and commercial value.
Combining an abnormal biomarker with a sensitive measure of cognition, like our MCI Screen™, is one possible solution to this diagnostic challenge. We are actively engaged with leading diagnostic manufacturers in collaborative efforts to develop a simple and accurate diagnostic test for clinical practice.